Acquired Resistance to KRAS G12C Inhibition in Cancer

🤖 Plain-English Summary

The mechanisms of acquired resistance to these therapies are currently unknown. CONCLUSIONS: inhibitors, and new therapeutic strategies are required to delay and overcome this drug resistance in patients with cancer.

🔑 Key Findings

CONCLUSIONS: inhibitors, and new therapeutic strategies are required to delay and overcome this drug resistance in patients with cancer.
(Funded by Mirati Therapeutics and others; ClinicalTrials.gov number, NCT03785249.).

💡 Why This Matters

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

Read the full paper
Access the original peer-reviewed research via OpenAlex.

View on DOI ↗

📜 Copyright Notice: This page shows only metadata (title, authors, journal, date) and an original AI-generated summary. No abstract or full article text is copied. The original research is the intellectual property of its authors and publisher. ScienceTrace does not reproduce copyrighted content.

← More Medicine & Biology All Research Articles

📋 Article Details

Category	🧬 Medicine & Biology
Published	Jun 23, 2021
Journal	New England Journal of Medicine
Authors	Mark M. Awad, Shengwu Liu, Igor I. Rybkin, Kathryn C. Arbour, Julien Dilly
DOI	10.1056/nejmoa2105281
Citations	1,156
Source	OpenAlex

🗂️ Research Categories

🤖 Artificial Intelligence 🧬 Medicine & Biology ⚛️ Physics & Space Science ⚙️ Engineering & Technology ∑ Mathematics